|

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

RECRUITINGSponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Actively Recruiting
SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
Started2025-02-04
Est. completion2044-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06788639

Summary

The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

• Participants must have been treated in the post-marketing setting with ≥1 infusion of lisocabtagene maraleucel used for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) within the approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA

Exclusion Criteria:

* Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion
* Patients treated with non-conforming CAR T-cell product

Conditions3

CancerChronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Locations1 site

Center for International Blood and Marrow Transplant Research (CIBMTR)
Milwaukee, Wisconsin, 53226

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.